Jupiter Neurosciences lands exclusive U.S. rights to ALA-002

Jupiter Neurosciences has signed a definitive license agreement for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based psychedelic candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives Jupiter a second clinical-stage CNS program alongside its Parkinson’s disease asset.

Why it matters: - Jupiter Neurosciences is moving from a single-program company to a dual clinical-stage central nervous system developer. - The agreement adds an FDA-designated Novel Chemical Entity and gives Jupiter long-term access to any U.S. commercialization upside. - The deal also deepens Jupiter’s position in psychedelic medicine at a time when the company sees a more favorable U.S. regulatory backdrop.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002. - The transaction was announced July 22, 2026. - The deal carries a potential value of up to $100 million, including milestone payments, excluding ongoing royalties. - Jupiter said the agreement expands its portfolio beyond its natural resveratrol program and into a second clinical-stage CNS asset.

The details: - Jupiter will pay $3.3 million upfront, split between $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - Jupiter owes a $3.3 million development milestone if ALA-002 reaches Phase 3 first patient in. - Jupiter owes a $20 million regulatory milestone upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when U.S. net sales reach $333 million, $1 billion and $2 billion. - Jupiter will owe a 3% royalty on net sales after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation with FDA Novel Chemical Entity designation. - The designation provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - The company says ALA-002 was engineered to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving therapeutic and pro-social effects. - PharmAla’s MDMA supply is already active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms still to be negotiated. - Jupiter said that arrangement should accelerate development timelines. - Jupiter’s lead program remains JOTROL, an enhanced-bioavailability resveratrol formulation in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia, a consumer longevity supplement. - Jupiter said the acquisition strengthens its CNS pipeline with a next-generation psychedelic NCE. - The company is listed on Nasdaq under JUNS. - Jupiter is a B2i Digital Featured Company, and its profile is available here.

Between the lines: - The deal gives Jupiter a second independent development path, which can reduce reliance on a single clinical program. - Perpetual U.S. rights are unusually durable for a licensing transaction and could matter if ALA-002 advances toward approval. - Management is also tying the transaction to the April 18, 2026 executive order on investigational psychedelic therapies, which it believes may speed development and review pathways. - The executive order directed federal agencies to expand access, including a Right to Try pathway, expedited review vouchers and $50 million in ARPA-H funding. - The company is also signaling a heavier focus on capital discipline and milestone-driven execution.

What's next: - Jupiter will work with PharmAla on manufacturing and commercial terms for ALA-002 drug supply. - The company will push both ALA-002 and JOTROL toward near-term clinical milestones. - Jupiter’s management said the next 12 months should be transformative for the company. - The transaction still faces the usual clinical, regulatory, financing and execution risks associated with early-stage drug development.

The bottom line: - Jupiter just bought itself a second shot on goal in CNS, with exclusive U.S. rights to a differentiated psychedelic asset and a clearer path to scale if the program advances.